Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy

Core Viewpoint - Annexon, Inc. is advancing targeted immunotherapies for neuroinflammatory diseases, with a focus on dry age-related macular degeneration (AMD) and geographic atrophy (GA), impacting nearly 10 million people globally [1][8] Company Overview - Annexon is a biopharmaceutical company specializing in immunotherapies aimed at neuroinflammatory diseases [1][8] - The company is developing vonaprument, a C1q inhibitor designed to be the first targeted vision-preserving therapy for GA [6][8] Event Announcement - Annexon will host a key opinion leader (KOL) event in New York on March 18, 2026, featuring presentations on dry AMD and GA [1][2] - The event will include a live Q&A session following the formal presentations [2] Expert Contributions - Dr. Eleonora Lad and Dr. Charles C. Wykoff will present at the event, focusing on the unmet needs in GA treatment and the mechanism of disease [5] - Dr. Lad's research includes the role of neuroinflammation in AMD and the development of innovative diagnostic approaches [3] - Dr. Wykoff has extensive experience in clinical trials and research related to retinal diseases [4] Product Development - Vonaprument is a clinical-stage investigational therapy that selectively inhibits C1q, aiming to protect retinal function [6] - The drug has received Fast Track designation from the FDA and Priority Medicine designation from the European Medicines Agency [6] Clinical Trial Information - The Phase 3 ARCHER II trial has enrolled over 630 patients with advanced dry AMD and GA, with a primary endpoint of preventing a ≥15-letter loss in best corrected visual acuity [7] - Topline data from the trial is expected in the second half of 2026 [7]